<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113940</url>
  </required_header>
  <id_info>
    <org_study_id>C4541003</org_study_id>
    <secondary_id>2021-004037-36</secondary_id>
    <nct_id>NCT05113940</nct_id>
  </id_info>
  <brief_title>A Study of PF-07258669 In Healthy Adult Participants</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacokinetic Interaction With Midazolam of Multiple Ascending Oral Doses of PF-07258669 in Healthy Non-Japanese and Japanese Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part A of this study is to evaluate safety, tolerability, and pharmacokinetics (PK) of&#xD;
      PF-07258669 after administration of multiple ascending oral doses to healthy adult&#xD;
      participants. A cohort of healthy adult Japanese participants may also be evaluated. Part B&#xD;
      of this study is a 2-period, fixed-sequence, multiple-dose, open-label design to evaluate the&#xD;
      effect of PF-07258669 on midazolam PK in healthy adult participants. Part B will be conducted&#xD;
      if the results of Part A support further evaluation of PF-07258669.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 3, 2021</start_date>
  <completion_date type="Anticipated">July 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A:Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)</measure>
    <time_frame>Baseline up to 35 days after last dose of study intervention (approximately 11 weeks).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Clinical Laboratory Abnormalities</measure>
    <time_frame>Baseline up to 10 days after last dose of study intervention (approximately 7 weeks).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Clinically Significant Change From Baseline in Vital Signs</measure>
    <time_frame>Baseline up to 10 days after last dose of study intervention (approximately 7 weeks).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Cardiac Rhythms of Potential Clinical Concern Assessed By Telemetry</measure>
    <time_frame>0 to 8 hours post-dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Cardiac Rhythms of Potential Clinical Concern Assessed By Telemetry</measure>
    <time_frame>0 to 8 hours post-dose on Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Cardiac Rhythms of Potential Clinical Concern Assessed By Telemetry</measure>
    <time_frame>0 to 8 hours post-dose on Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline up to 10 days after last dose of study intervention (approximately 7 weeks).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Clinically-Significant Change From Baseline in Physical Examination Findings</measure>
    <time_frame>Baseline up to 10 days after last dose of study intervention (approximately 7 weeks).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Clinically-Significant Change From Baseline in Neurological Examination Findings</measure>
    <time_frame>Baseline up to 10 days after last dose of study intervention (approximately 7 weeks).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>C-SSRS is a questionnaire to assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced following: completed suicide; suicide attempt (response of &quot;Yes&quot; on &quot;actual attempt&quot;); preparatory acts toward imminent suicidal behavior (&quot;Yes&quot; on &quot;preparatory acts or behavior&quot;, &quot;aborted attempt&quot; or &quot;interrupted attempt&quot;), suicidal ideation (&quot;Yes&quot; on &quot;wish to be dead&quot;, &quot;non-specific active suicidal thoughts&quot;, &quot;active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent, any self-injurious behavior with no suicidal intent). In this outcome, number of participants with positive response (response of &quot;yes&quot;) to suicidal behavior, ideation or any self-injurious behavior, at Day 14 were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Maximum Observed Plasma Concentration (Cmax) of Midazolam</measure>
    <time_frame>Time Frame: predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Period 1/Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Maximum Observed Plasma Concentration (Cmax) of Midazolam</measure>
    <time_frame>Time Frame: predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Period 2/Day 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Maximum Observed Plasma Concentration (Cmax) of Midazolam</measure>
    <time_frame>Time Frame: predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Period 2/Day10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUClast) of Midazolam</measure>
    <time_frame>Time Frame: predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Period 1/Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUClast) of Midazolam</measure>
    <time_frame>Time Frame: predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Period 2/Day 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUClast) of Midazolam</measure>
    <time_frame>Time Frame: predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Period 2/Day10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Area under the plasma concentration-time curve from time 0 to Extrapolated Infinite Time (AUCinf) of Midazolam</measure>
    <time_frame>Time Frame: predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Period 1/Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Area under the plasma concentration-time curve from time 0 to Extrapolated Infinite Time (AUCinf) of Midazolam</measure>
    <time_frame>Time Frame: predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Period 2/Day 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Area under the plasma concentration-time curve from time 0 to Extrapolated Infinite Time (AUCinf) of Midazolam</measure>
    <time_frame>Time Frame: predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Period 2/Day10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Maximum Observed Plasma Concentration (Cmax) of PF-07258669</measure>
    <time_frame>Time Frame: predose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours post dose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Maximum Observed Plasma Concentration (Cmax) of PF-07258669</measure>
    <time_frame>Time Frame: predose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours post dose on Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Dose Normalized Maximum Observed Plasma Concentration (Dose-Normalized Cmax) of PF-07258669</measure>
    <time_frame>Time Frame: predose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours post dose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Dose Normalized Maximum Observed Plasma Concentration (Dose-Normalized Cmax) of PF-07258669</measure>
    <time_frame>Time Frame: predose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours post dose on Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Area Under the Plasma Concentration-Time Curve From Time 0 to Dosing Interval (tau) (AUCtau) of PF-07258669</measure>
    <time_frame>Time Frame: predose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours post dose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Area Under the Plasma Concentration-Time Curve From Time 0 to Dosing Interval (tau) (AUCtau) of PF-07258669</measure>
    <time_frame>Time Frame: predose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours post dose on Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Dose Normalized Area Under the Curve from Time 0 to Dosing Interval (tau) (Dose-Normalized AUCtau) of PF-07258669</measure>
    <time_frame>Time Frame: predose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours post dose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Dose Normalized Area Under the Curve from Time 0 to Dosing Interval (tau) (Dose-Normalized AUCtau) of PF-07258669</measure>
    <time_frame>Time Frame: predose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours post dose on Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-07258669</measure>
    <time_frame>Time Frame: predose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours post dose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-07258669</measure>
    <time_frame>Time Frame: predose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours post dose on Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Amount of PF-0728669 Excreted Unchanged in Urine Over the Dosing Interval Tau (Aetau)</measure>
    <time_frame>On Day 14, urine collection for PK to occur over 0-tau, according to dosing frequency (ie, 0-8 hours for 8 hour dosing interval; 0-12 hours for 12 hour dosing interval)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Percentage of Dose of PF-07258669 Excreted Unchanged in the Urine Over the Dosing Interval Tau (Aetau%)</measure>
    <time_frame>On Day 14, urine collection for PK to occur over 0-tau, according to dosing frequency (ie, 0-8 hours for 8 hour dosing interval; 0-12 hours for 12 hour dosing interval)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Renal Clearance of PF-07258669</measure>
    <time_frame>On Day 14, urine collection for PK to occur over 0-tau, according to dosing frequency (ie, 0-8 hours for 8 hour dosing interval; 0-12 hours for 12 hour dosing interval)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)</measure>
    <time_frame>Baseline up to 35 days after last dose of study intervention (approximately 10 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Participants With Clinically Significant Change From Baseline in Vital Signs</measure>
    <time_frame>Baseline up to 10 days after last dose of study intervention (approximately 7 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Participants With Oxygen Saturation Levels of Potential Clinical Concern</measure>
    <time_frame>0 to 6 hours post-dose on Period 1/Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Participants With Oxygen Saturation Levels of Potential Clinical Concern</measure>
    <time_frame>0 to 6 hours post-dose on Period 2/Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Participants With Oxygen Saturation Levels of Potential Clinical Concern</measure>
    <time_frame>0 to 6 hours post-dose on Period 2/Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline up to 10 days after last dose of study intervention (approximately 7 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Participants With Clinical Laboratory Abnormalities</measure>
    <time_frame>Baseline up to 10 days after last dose of study intervention (approximately 7 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Participants With Clinically-Significant Change From Baseline in Physical Examination Findings</measure>
    <time_frame>Baseline up to 35 days after last dose of study intervention (approximately 10 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>PF-07258669 and Placebo (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 1: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-07258669 and Placebo (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 2: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-07258669 and Placebo ((Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 3: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-07258669 and Placebo (Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 4: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-07258669 and Placebo (Cohort 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 5: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-07258669 and Placebo (Cohort 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 6: Multiple dose administration of PF-07258669 and placebo over 14 days in Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam with and without PF-07258669 (Cohort 7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug-drug interaction assessment of pharmacokinetics interaction in PF-07258669 and midazolam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07258669</intervention_name>
    <description>PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days</description>
    <arm_group_label>Midazolam with and without PF-07258669 (Cohort 7)</arm_group_label>
    <arm_group_label>PF-07258669 and Placebo ((Cohort 3)</arm_group_label>
    <arm_group_label>PF-07258669 and Placebo (Cohort 1)</arm_group_label>
    <arm_group_label>PF-07258669 and Placebo (Cohort 2)</arm_group_label>
    <arm_group_label>PF-07258669 and Placebo (Cohort 4)</arm_group_label>
    <arm_group_label>PF-07258669 and Placebo (Cohort 5)</arm_group_label>
    <arm_group_label>PF-07258669 and Placebo (Cohort 6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered as tablets; Q8H or Q12H over 14 days</description>
    <arm_group_label>PF-07258669 and Placebo ((Cohort 3)</arm_group_label>
    <arm_group_label>PF-07258669 and Placebo (Cohort 1)</arm_group_label>
    <arm_group_label>PF-07258669 and Placebo (Cohort 2)</arm_group_label>
    <arm_group_label>PF-07258669 and Placebo (Cohort 4)</arm_group_label>
    <arm_group_label>PF-07258669 and Placebo (Cohort 5)</arm_group_label>
    <arm_group_label>PF-07258669 and Placebo (Cohort 6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07258669</description>
    <arm_group_label>Midazolam with and without PF-07258669 (Cohort 7)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female participants of nonchildbearing potential and male participants who are overtly&#xD;
             healthy as determined by medical evaluation including medical history, physical&#xD;
             examination, laboratory tests, and cardiac monitoring.&#xD;
&#xD;
          2. Participants who are willing to avoid direct sunlight exposure or any high intensity&#xD;
             ultraviolet light exposure from admission to the follow-up contact and to apply&#xD;
             sunscreen/lotion with a high sun protection factor and to wear eye protection, as&#xD;
             appropriate.&#xD;
&#xD;
          3. Body mass index (BMI) of 17.5 to 28.5 kg/m2; and a total body weight &gt;50 kg (110 lb).&#xD;
&#xD;
          4. Japanese participants only: Participants enrolling as Japanese must have 4 biological&#xD;
             Japanese grandparents who were born in Japan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence or history of clinically significant hematological, renal, endocrine&#xD;
             (including thyroid), pulmonary, gastrointestinal, cardiovascular, hepatic,&#xD;
             psychiatric, neurological, or allergic disease (including drug allergies, but&#xD;
             excluding untreated, asymptomatic, seasonal allergies at the time of dosing), as well&#xD;
             as presence of lipid panel abnormalities defined below (eg, hypercholesterolemia,&#xD;
             hypertriglyceridemia).&#xD;
&#xD;
          2. History of symptomatic orthostatic hypotension or symptomatic bradycardia.&#xD;
&#xD;
          3. History of eating disorders (eg, anorexia or bulimia nervosa).&#xD;
&#xD;
          4. Use of prescription or nonprescription drugs and dietary and herbal supplements within&#xD;
             7 days or 5 half-lives (whichever is longer) prior to the first dose of study&#xD;
             intervention.&#xD;
&#xD;
          5. Use of moderate or strong cytochrome p-450 3A (CYP3A) inhibitors or inducers within 28&#xD;
             days or 5 half-lives (whichever is longer) prior to first dose of study intervention.&#xD;
&#xD;
          6. Previous administration with an investigational drug within 30 days (or as determined&#xD;
             by the local requirement) or 5 half-lives preceding the first dose of study&#xD;
             intervention used in this study (whichever is longer).&#xD;
&#xD;
          7. Any lipid panel parameter except high-density lipoprotein (HDL) (ie, total&#xD;
             cholesterol, triglycerides, and/or low-density lipoprotein (LDL)) ≥1.25× upper limit&#xD;
             of normal (ULN).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brussels Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-capitale, Région DE</state>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4541003</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PF-07258669</keyword>
  <keyword>multiple dose</keyword>
  <keyword>melanocortin-4 receptor</keyword>
  <keyword>MC4R</keyword>
  <keyword>healthy participants</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

